Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2019

04.04.2019 | Brief Research Article

Neuroblastoma: validation of the INRG classification system in a small series

verfasst von: E. Ramos Elbal, A. M. Galera Miñarro, M. E. Llinares Riestra, M. Bermúdez Cortés, J. L. Fuster Soler

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In 2009, the International Neuroblastoma Risk Group (INRG) published a new classification system of the childhood neuroblastic tumors. In this work, we present the results of the application of this new classification system in our patients.

Methods/patients

We conducted a retrospective analysis of the patients diagnosed with a neuroblastic tumor in our center in the last 20 years. We classified them according to the new classification and performed a survival analysis based on the Kaplan–Meier method and Mantel–Cox test.

Results

The five-year event-free survival (5-year EFS) was 95.8, 80.8, 50 and 45.9% for the very low, low, intermediate and high-risk groups. Mantel–Cox test showed statistically significant differences between these risk groups (p = 0.002).

Conclusion

The 5-year EFS for the different risk groups was similar to the expected by the INRG. Therefore, this classification allows us to predict the evolution of this tumor and apply the correct intensity of treatment.
Literatur
1.
Zurück zum Zitat Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20.CrossRef Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20.CrossRef
2.
Zurück zum Zitat Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat RevCancer. 2003;3(3):203–16.CrossRef Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat RevCancer. 2003;3(3):203–16.CrossRef
3.
Zurück zum Zitat Torbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018;372(2):195–209.CrossRef Torbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018;372(2):195–209.CrossRef
4.
Zurück zum Zitat Pinto NR, Applebaum MA, Volchenboum SL, Matthay K, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17.CrossRef Pinto NR, Applebaum MA, Volchenboum SL, Matthay K, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17.CrossRef
5.
Zurück zum Zitat Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D’Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6(12):1874–81.CrossRef Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D’Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6(12):1874–81.CrossRef
6.
Zurück zum Zitat Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466–77.CrossRef Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466–77.CrossRef
7.
Zurück zum Zitat Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–97.CrossRef Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–97.CrossRef
8.
Zurück zum Zitat Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Ceccheto G, Holmes K, et al. The International Neuroblastoma risk Group (INRG) staging system: an INRG Task Force Report. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Ceccheto G, Holmes K, et al. The International Neuroblastoma risk Group (INRG) staging system: an INRG Task Force Report.
Metadaten
Titel
Neuroblastoma: validation of the INRG classification system in a small series
verfasst von
E. Ramos Elbal
A. M. Galera Miñarro
M. E. Llinares Riestra
M. Bermúdez Cortés
J. L. Fuster Soler
Publikationsdatum
04.04.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02099-7

Weitere Artikel der Ausgabe 12/2019

Clinical and Translational Oncology 12/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.